Our Response to COVID-19

EXBIO products DryFlowEx ASC Screening Kit and DryFlowEx ACT T Screening Kit in practice

EXBIO has recently developed two new products for multicolor flow-cytometric immunophenotyping of cells of the human immune system from peripheral blood to follow up kinetics of immune responses in relation to clinical and virological features of a COVID-19 patients. Design of these new products reflects the recently published reports (1,2,3).
 
Now, we bring you a presentation of patient’s data – comparision with percentage range acquired from normal healthy donors and time-course changes in subpopulations of B and T cells of hospitalized patients diagnosed with COVID-19 – day 1, day 4 and day 11 from hospitalization.
 
Our products DryFlowEx ASC Screening Kit and DryFlowEx ACT T Screening Kit are designed for very simple use - in order to minimize hands-on-time and contacts with the infectious blood specimen, the reagents are provided in a ready-to-use single-test tube format. Each tube (standard 12 x 75 mm flow cytometry tube) contains a layer with the dried pre-formulated mixture of antibody conjugates for direct labeling of target cells.
 
Simple laboratory workflow enables operator to follow just three easy steps:

• add whole blood specimen to the test tube, vortex and incubate;
• lyse erythrocytes with EXCELLYSE Easy (ED7066) lysing solution and wash;
• acquire sample and get cytometry data.

 

DryFlowEx ASC Screening Kit

Table 1 – Target population(s) percentage range acquired from normal healthy human whole blood specimens
 

		95% Range
n=15	Avg	Min. (Avg - 2 SD)	Max. (Avg + 2 SD)
Class-switched Plasmablasts	1,18%	0,00%	2,50%
Non-switched Plasmablasts	0,03%	0,00%	0,08%

 
Fig. 1 Target population(s) percentage change in time acquired from whole blood specimens of hospitalized patients diagnosed with COVID-19

DryFlowEx ACT T Screening Kit

Table 2 – Target population(s) percentage range acquired from normal healthy human whole blood specimens 
 

		95% Range
n=15	Avg	Min. (Avg - 2 SD)	Max. (Avg + 2 SD)
Circulating Folicular Helper T-cells	2,24%	0,90%	3,59%
Activated CD3+ CD4+ T-cells	0,66%	0,29%	1,03%
Activated CD3+ CD8+ T-cells	0,67%	0,00%	1,60%

 
Fig. 2 Target population(s) percentage change in time acquired from whole blood specimens of hospitalized patients diagnosed with COVID-19

 
FOR SPECIAL  25% DISCOUNT ON PRODUCTS TO SUPPORT LABORATORIES TESTING COVID-19 PATIENT SAMPLES PLEASE MENTION ON YOUR PURCHASE ORDER THE FOLLOWING DISCOUNT CODE CQ1200287.

 
Technical and application support: technical@exbio.cz
Availability of products, price quotations: info@exbio.cz
Orders: orders@exbio.cz

(1) Thevarajan, I., Nguyen, T.H.O., Koutsakos, M. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med (2020).
(2) Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med (2020).
(3) Guang Chen G., Zhao J., Ning Q. et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. (2020).